Strong new ESG rating puts Grünenthal in top 2% of the pharmaceuticals subindustry
The latest independent rating confirms Grünenthal’s improved approach to managing Environmental, Social and Governance (ESG) topics – and evaluates the company as the leader in its peer group, with a low ESG risk rating.
Stakeholders expect businesses to meet high standards for sustainability and responsibility. Investors seeking attractive long-term opportunities also pay close attention to how a company manages Environmental, Social and Governance (ESG) topics.
In this context, ESG risk ratings conducted by independent organisations offer stakeholders a trustworthy indication of a company’s impact on people and the planet. And the latest assessment by Sustainalytics, a leading ESG risk rating provider, ranks Grünenthal in the top 2% for the pharmaceuticals subindustry1 – with even stronger scores than in the previous year.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance